Scope
NICE guideline NG220 covers the recognition, diagnosis and ongoing management of multiple sclerosis (MS) in adults. It includes recommendations from 2014, 2022 and amendments to 2026. Topics are referral and diagnosis using the 2024 revised McDonald criteria, information and support, care coordination, modifiable risk factors, symptom management and the annual comprehensive review. It also covers diagnosis and treatment of relapse, and signposting to technology appraisals for disease-modifying therapies by MS subtype.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Recognition, referral and diagnosis
- Common presentations include visual loss in 1 eye with painful eye movements, ascending sensory disturbance and/or weakness, and progressive difficulty with balance and gait. People are often under 50, symptoms evolve over more than 24 hours, and there is no fever or infection. [1]
- Do not routinely suspect MS when the main complaints are fatigue, depression, dizziness or vague sensory symptoms. The exception is when there is a history or evidence of focal neurological symptoms or signs. [1]
- Before referral, use history and examination to confirm a neurological episode and exclude more common alternatives. Refer for diagnosis by a consultant neurologist or a supervised specialist, and contact the neurologist directly when urgent. Ophthalmologist-confirmed isolated optic neuritis should also be referred to a consultant neurologist. [1]
- Make the diagnosis by combining history, examination, MRI and laboratory results, and apply the 2024 revised McDonald criteria. If the criteria are not met but MS is suspected, or clinically isolated syndrome is confirmed, plan a review to reassess MS and discuss the timing of this and later reviews with the person (for example, annually). Make sure they know whom to contact if symptoms are new or worsening. [1]
Information, coordination and comprehensive review
- At diagnosis, the consultant neurologist should ensure that oral and written information is offered. This goes to the person and, with their agreement, to family or carers, and includes legal duties such as DVLA notification. Explore social care needs and refer to social services if needed. Offer a face-to-face follow-up with an MS-experienced professional within 6 weeks. [1]
- Offer a single point of contact who knows local MS services, and deliver care through a coordinated multidisciplinary team. [1]
- Ask about family plans soon after diagnosis and at intervals. People on disease-modifying therapy should report trying to conceive, or pregnancy, straight away. Discussion may cover several points: fertility is unaffected; relapses may fall in pregnancy and rise 3 to 6 months postpartum; breastfeeding is safe unless certain disease-modifying therapies are used. [1]
- Everyone with MS needs a comprehensive review of all aspects of care at least once a year by MS-experienced professionals, tailored to the person's needs; the disease-course assessment includes eligibility for disease-modifying therapy. Refer issues identified to the MS multidisciplinary team. [1]
- Assess bone health regularly. Where mobility is severely reduced, review contracture risk regularly and check pressure-ulcer risk areas at every contact. [1]
Modifiable risk factors and other treatments
- Encourage exercise, explaining that it may benefit MS and does not harm it. Advise against smoking because it increases disability progression. Offer vaccinations to people with MS and their carers in line with JCVI and Green Book advice. Do not offer vitamin D solely to treat MS. Do not offer omega-3 or omega-6 fatty acids to treat MS, because there is no evidence they affect relapse frequency or progression. [1]
Symptom management
- Ask about fatigue or changes in energy that affect daily life. Do not assume MS is the cause. Assess and manage alternative causes, such as infection, anaemia or thyroid dysfunction, or refer for their management. [1]
- Offer a personalised discussion on self-managing fatigue, and advise that aerobic, resistive and balance exercise, including yoga and pilates, may help. With EDSS 4 or above, consider supervised aerobic and moderate progressive resistance activity combined with cognitive behavioural techniques. Vitamin B12 injections and hyperbaric oxygen should not be used for fatigue. [1]
- If a person wants to try medicine for fatigue, refer them to a specialist and use shared decision making to decide whether to try one and which. Options to consider include amantadine (dosing per the BNF) or an SSRI at the lowest dose recommended for licensed indications. Review effectiveness, safety and acceptability regularly and decide whether to continue or stop. [1]
- Modafinil is another option to consider, except in people who are pregnant or planning pregnancy. Follow MHRA safety advice, including cardiovascular monitoring before and during treatment. For people able to get pregnant, follow MHRA pregnancy advice: explain the risks, advise effective contraception and explain that modafinil may reduce the effectiveness of steroidal contraceptives. Use the lowest effective dose. [1]
- For spasticity, look for aggravating factors such as pressure ulcers, bladder or bowel dysfunction, infection, poor posture and pain. Explain that some people use their spasticity to maintain posture and the ability to stand, walk or transfer, and that muscle relaxants may adversely affect this. Consider oral baclofen first-line when there are specific goals. Consider gabapentin second-line if baclofen is not tolerated or inadequate. [1]
- Increase baclofen or gabapentin in increments of at least 2 weeks to effect or the maximum tolerated dose. Stop if there is no benefit at the maximum tolerated dose, warning that abrupt baclofen withdrawal is harmful. Review at least annually once the dose is optimal. A combination may be considered if single agents are inadequate, with caution about respiratory depression. Refer persistent significant impairment to a spasticity MDT. [1]
- Investigate the cause of pain and treat accordingly. Manage neuropathic pain, including referral to pain services, under the neuropathic pain guideline. Musculoskeletal pain is common and usually stems from immobility, spasticity and posture. [1]
- Assess cognition during the comprehensive review, using an interview, a brief formal test or neuropsychological referral as needed. Anxiety, depression, sleep difficulty, fatigue and medication can affect cognition, so assess for these and offer appropriate management. Consider occupational therapy and/or neuropsychology referral for persisting impairment. [1]
Relapse
- Diagnose a relapse when new or worsening symptoms last more than 24 hours, have no infection or other cause, and follow at least 1 month of stability. First exclude infection, particularly urinary and respiratory, and distinguish relapse from fluctuation or progression. Do not routinely diagnose relapse when symptoms have lasted over 3 months. [1]
- Relapses that impair usual tasks should be assessed and treatment offered as early as possible, within 14 days of onset. Non-specialists should discuss steroid use with an MS-experienced professional, since not every relapse needs steroids. Offer inpatient care for severe relapses or when needs cannot be met at home. [1]
- Offer oral methylprednisolone 0.5 g daily for 5 days. Consider IV methylprednisolone 1 g daily for 3 to 5 days if oral steroids fail or are not tolerated, or if admission is needed for severe relapse or monitoring of conditions such as diabetes. Do not use lower doses or provide home steroid supplies for future relapses. [1]
Disease-modifying therapies
- For active relapsing–remitting MS, the options are those recommended in the linked NICE technology appraisals, including ocrelizumab, ofatumumab and teriflunomide among others. Ozanimod and interferon beta-1b (Betaferon) are not recommended. [1]
- For highly active RRMS with activity on treatment, appraised options include subcutaneous originator or IV biosimilar natalizumab and fingolimod. IV originator natalizumab is not recommended. For rapidly evolving severe RRMS, options include alemtuzumab. NHS England endorses fingolimod as an alternative to natalizumab when progressive multifocal leukoencephalopathy risk is high. [1]
- Siponimod is an option for secondary progressive MS with active disease (relapses or inflammatory imaging). Extavia is an option when relapses continue. Betaferon is not recommended by the appraisal, but NHS England permits it at clinical discretion because Extavia is discontinued. Ocrelizumab is an option for early primary progressive MS with inflammatory imaging features. [1]
Limitations and use
- Applies to adults with MS; the guideline does not address all MS symptoms and defers some to other NICE guidelines.
- Disease-modifying therapy eligibility and criteria are set out in the individual technology appraisals, which were not reviewed here.
- The fampridine recommendation was withdrawn in favour of an NHS England commissioning policy. THC:CBD spray for spasticity is covered by the cannabis-based medicinal products guideline.
- For pharmacological management of ataxia and tremor, only a research recommendation was made, so no clinical recommendation exists.
- Research recommendations, rationale and committee discussion were not part of the reviewed text.
- Off-label status of amantadine, modafinil, SSRIs, gabapentin, memantine and amitriptyline is stated as of June 2022.
- This summary is selective, and many clinically material recommendations are omitted. The following are examples only, not an exhaustive list: NMOSD diagnosis; ongoing information and support, including advanced MS, end-of-life care and advance care planning (1.2.4–1.2.10, 1.2.14–1.2.18); the pharmacological fatigue discussion and shared-care prescribing (1.5.12, 1.5.16); mobility assessment, vestibular rehabilitation and supervised exercise programmes (1.5.17, 1.5.19–1.5.23); suspecting spasticity (1.5.24); oscillopsia; and emotional lability. Further examples are medicines review, carers and palliative referral (1.6.5, 1.6.9–1.6.10); local relapse pathways and follow-up (1.7.4); and relapse information and steroid side-effect counselling, MDT notification, cognition and social care at relapse (1.7.11–1.7.15, 1.7.17–1.7.18).
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Multiple sclerosis in adults: management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 22 June 2022
- Publisher’s latest update
- 26 August 2026
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.